Vinicius Ernani is an Oncology physician affiliated with WinnMed. OpenAlex indexes 96 publications with 1,327 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Provider last certified this registry record 9 Sept 2020.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20258 payments
- Aveo Pharmaceuticals, Inc.Program year20251 payment
- Janssen Biotech, Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73%PD-1 inhibitor22.3%Pembrolizumab65%Nivolumab35%Part B, office-administered≥50 patientsCD38-directed Cytolytic Antibody14.5%Daratumumab100%Part B, office-administered≥58 patients+ 11 more classes in this area
Metabolism & gastrointestinal
13.9%Other antiemetics10.9%Fosaprepitant100%Part B, office-administered≥58 patientsSerotonin-3 Receptor Antagonist2.3%Palonosetron hcl55%Ondansetron hydrochloride42%Ondansetron Hcl3%Part D + Part B≥102 patients+ 4 more classes in this area
Blood & clotting
5.5%Erythropoiesis-stimulating Agent5.5%Darbepoetin alfa100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.1%Eliquis80%Xarelto20%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evolving Field of Immunotherapy: Pioneering New Paths in Small-Cell Lung Cancer
JCO Oncology Practice
2025 - Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Mayank Sardana, MD
WinnMed
Rakesh Suri, MD
WinnMed
Jorge Rakela, MD
WinnMed
Hugo Vargas, MD
WinnMed
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”